0001415889-22-010878.txt : 20221028
0001415889-22-010878.hdr.sgml : 20221028
20221028161518
ACCESSION NUMBER: 0001415889-22-010878
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221026
FILED AS OF DATE: 20221028
DATE AS OF CHANGE: 20221028
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Iwicki Mark T
CENTRAL INDEX KEY: 0001415537
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38150
FILM NUMBER: 221342033
MAIL ADDRESS:
STREET 1: 84 WATERFORD DRIVE
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kala Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001479419
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270604595
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
BUSINESS PHONE: 781-996-5252
MAIL ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
4
1
form4-10282022_041001.xml
X0306
4
2022-10-26
0001479419
Kala Pharmaceuticals, Inc.
KALA
0001415537
Iwicki Mark T
C/O KALA PHARMACEUTICALS, INC.
1167 MASSACHUSETTS AVENUE
ARLINGTON
MA
02476
true
true
false
false
CHIEF EXECUTIVE OFFICER
Common Stock
2022-10-26
4
S
0
561
6.52
D
4464
D
This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.62, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Includes 1,014 unvested RSUs.
The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.
/s/ Eric Trachtenberg, Attorney-in-Fact
2022-10-28